Foresite Capital Management II’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Foresite Capital Management II’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-80,500	Closed	-$1.36M	–	12
2018 Q3	$1.36M	Hold	80,500	–	–	0.5%	10
2018 Q2	$1.14M	Buy	80,500 +34,362	+74%	+$571K	0.4%	9
2018 Q1	$877K	Buy	+46,138	New	+$986K	0.29%	10
2017 Q3	–	Sell	-46,000	Closed	-$405K	–	15
2017 Q2	$405K	Buy	+46,000	New	+$295K	0.19%	12
2015 Q2	–	Sell	-165,000	Closed	-$2.59M	–	23
2015 Q1	$2.59M	Buy	+165,000	New	+$2.55M	1.53%	15

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Foresite Capital Management II's SGMO Position: Q4 2018 in Review

Foresite Capital Management II sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2018, closing a stake of 80,500 shares — an estimated $1.36M sold.

Foresite Capital Management II first reported a position in SGMO in Q1 2015 and held it in 5 quarters. The position peaked at $2.59M in Q1 2015. 197 funds tracked by Wall St. Rank hold SGMO as of Q4 2018.

Foresite Capital Management II reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2018 after selling out during the quarter.
Foresite Capital Management II sold 80,500 SANGAMO THERAPEUTICS INC shares in Q4 2018, an estimated $1.36M.
Foresite Capital Management II first reported a position in SANGAMO THERAPEUTICS INC in Q1 2015 and held it in 5 quarters.
Foresite Capital Management II's SANGAMO THERAPEUTICS INC position peaked at $2.59M in Q1 2015.
197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2018.

Based on Foresite Capital Management II's 13F filing for Q4 2018, filed 13 Feb 2019.